prednisolone sodium phosphate 2.5 MG/ML / sulfacetamide sodium 100 MG/ML Ophthalmic Solution

What the CMS Formulary Data Shows for prednisolone sodium phosphate 2.5 MG/ML / sulfacetamide sodium 100 MG/ML Ophthalmic Solution

Per the CMS 2026 Part D formulary file, prednisolone sodium phosphate 2.5 MG/ML / sulfacetamide sodium 100 MG/ML Ophthalmic Solution (RxNorm concept RXCUI 1012021, generic name prednisolone sodium phosphate) appears on 327 distinct formulary files spanning 5,048 Medicare Part D plan offerings - 99.6% of enrollable Part D products, near-universal placement. Tier placement ranges from Tier 1 to Tier 4, with a cross-plan average of Tier 1.8.

Real-world access to prednisolone sodium phosphate 2.5 MG/ML / sulfacetamide sodium 100 MG/ML Ophthalmic Solution depends on utilization management as much as tier placement: 0% of covering formularies require prior authorization. 0% require step therapy. 0.6% apply quantity limits.

Historical spending context from the CMS Medicare Part D Drug Spending Dashboard shows 21,651 Part D beneficiaries filled prednisolone sodium phosphate 2.5 MG/ML / sulfacetamide sodium 100 MG/ML Ophthalmic Solution in 2023, with total plan-and-beneficiary spending of $1,023,806 and an average per-beneficiary annual cost of $47.29. The plan-by-plan detail below lists exactly which PDP and MA-PD contracts carry prednisolone sodium phosphate 2.5 MG/ML / sulfacetamide sodium 100 MG/ML Ophthalmic Solution today.